Physician profile
Frank Chen
NPI 1932294584
$940,722.94
in general payments reported to CMS, 2019-2025
23 companies · $359K in 2025
The $359K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121K · 2020: $30K · 2021: $49K · 2022: $59K · 2023: $174K · 2024: $149K · 2025: $359K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $576K · Travel and Lodging: $53K · Food and Beverage: $19K · Consulting Fee: $18K · Honoraria: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $575,551.50 |
| Travel and Lodging | $53,285.46 |
| Food and Beverage | $19,189.97 |
| Consulting Fee | $17,973.50 |
| Honoraria | $16,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $369,076.26 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $249,960.79 | 2020-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $174,171.86 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Abilify Mycite |
| E.R. Squibb & Sons, L.L.C. | $113,332.04 | 2024-2025 | Cobenfy |
| Luye Pharma (USA) Ltd. | $18,462.86 | 2025 | Erzofri Extended-Release |
| Eli Lilly and Company | $7,300.00 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $7,242.81 | 2019-2025 | Rejoyn, Abilify Asimtufii, Rexulti |
| Allergan, INC. | $239.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $239.33 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Abbvie INC. | $177.38 | 2023-2025 | Vraylar |
| Axsome Therapeutics, INC. | $105.19 | 2024-2025 | Auvelity |
| Indivior INC. | $84.01 | 2019-2024 | Sublocade, Perseris |
| Lundbeck LLC | $73.91 | 2019-2024 | Rexulti |
| Janssen Scientific Affairs, LLC | $56.11 | 2019 | |
| Vanda Pharmaceuticals INC. | $44.16 | 2025 | Fanapt, Hetlioz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $30.44 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.22 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $21.55 | 2024 | Ingrezza |
| Corium, LLC | $18.50 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.70 | 2023 | Quviviq |
| Bausch Health US, LLC | $15.46 | 2020 | |
| Biogen, INC. | $15.10 | 2024 | |
| Arbor Pharmaceuticals, INC. | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.